Compare · CATX vs MDLN
CATX vs MDLN
Side-by-side comparison of Perspective Therapeutics Inc. (CATX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CATX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.16B, about 130.4x CATX ($353.9M).
- Over the past year, CATX is down 6.3% and MDLN is down 13.8% - CATX leads by 7.5 points.
- MDLN has been more active in the news (5 items in the past 4 weeks vs 4 for CATX).
- MDLN has more recent analyst coverage (25 ratings vs 12 for CATX).
PerformanceCATX+20.27%MDLN-13.82%
2025-12-17+0.00%2026-09-01
- Company
- Perspective Therapeutics Inc.
- Medline Inc.
- Price
- $3.12-1.11%
- $35.12+0.29%
- Market cap
- $353.9M
- $46.16B
- 1M return
- +3.49%
- -13.22%
- 1Y return
- -6.32%
- -13.82%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 5
- Recent ratings
- 12
- 25
Latest CATX
- BMO Capital Markets initiated coverage on Perspective Therapeutics with a new price target
- SEC Form 10-Q filed by Perspective Therapeutics Inc.
- Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
- SEC Form SCHEDULE 13G filed by Perspective Therapeutics Inc.
- Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
- Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
- Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.